Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

被引:63
作者
Bian, Yuemin [1 ,2 ,3 ,4 ]
Xie, Xiang-Qun [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Pharm, Computat Chem Genom Screening Ctr, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, NIH, Natl Ctr Excellence Computat Drug Abuse Res, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15261 USA
[5] Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15261 USA
[6] Univ Pittsburgh, Sch Med, Dept Struct Biol, Pittsburgh, PA 15261 USA
关键词
fragment-based drug design; fragment database; drug discovery; fragment docking; virtual screening; DE-NOVO DESIGN; MOLECULAR DOCKING; GENETIC ALGORITHM; INFORMATICS; FLEXIBILITY; GENERATION; INHIBITORS; DISCOVERY; LIBRARIES; FAMILY;
D O I
10.1208/s12248-018-0216-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fragment-based drug design (FBDD) has become an effective methodology for drug development for decades. Successful applications of this strategy brought both opportunities and challenges to the field of Pharmaceutical Science. Recent progress in the computational fragment-based drug design provide an additional approach for future research in a time-and labor-efficient manner. Combining multiple in silico methodologies, computational FBDD possesses flexibilities on fragment library selection, protein model generation, and fragments/compounds docking mode prediction. These characteristics provide computational FBDD superiority in designing novel and potential compounds for a certain target. The purpose of this review is to discuss the latest advances, ranging from commonly used strategies to novel concepts and technologies in computational fragment-based drug design. Particularly, in this review, specifications and advantages are compared between experimental and computational FBDD, and additionally, limitations and future prospective are discussed and emphasized.
引用
收藏
页数:11
相关论文
共 55 条
[1]   Constitutive activation of STAT3 in breast cancer cells: A review [J].
Banerjee, Kasturi ;
Resat, Haluk .
INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (11) :2570-2578
[2]   Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5 [J].
Bian, Yuemin ;
Feng, Zhiwei ;
Yang, Peng ;
Xie, Xiang-Qun .
AAPS JOURNAL, 2017, 19 (04) :1235-1248
[3]   A benchmark testing ground for integrating homology modeling and protein docking [J].
Bohnuud, Tanggis ;
Luo, Lingqi ;
Wodak, Shoshana J. ;
Bonvin, Alexandre M. J. J. ;
Weng, Zhiping ;
Vajda, Sandor ;
Schueler-Furman, Ora ;
Kozakov, Dima .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2017, 85 (01) :10-16
[4]   Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes [J].
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :1-14
[5]   A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].
Card, GL ;
Blasdel, L ;
England, BP ;
Zhang, C ;
Suzuki, Y ;
Gillette, S ;
Fong, D ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207
[6]   Homology modeling in drug discovery: current trends and applications [J].
Cavasotto, Claudio N. ;
Phatak, Sharangdhar S. .
DRUG DISCOVERY TODAY, 2009, 14 (13-14) :676-683
[7]   Evolutions in fragment-based drug design: the deconstruction-reconstruction approach [J].
Chen, Haijun ;
Zhou, Xiaobin ;
Wang, Ailan ;
Zheng, Yunquan ;
Gao, Yu ;
Zhou, Jia .
DRUG DISCOVERY TODAY, 2015, 20 (01) :105-113
[8]   Molecular docking and ligand specificity in fragment-based inhibitor discovery [J].
Chen, Yu ;
Shoichet, Brian K. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (05) :358-364
[9]   Impact of linker strain and flexibility in the design of a fragment-based inhibitor [J].
Chung, Suhman ;
Parker, Jared B. ;
Bianchet, Mario ;
Amzel, L. Mario ;
Stivers, James T. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (06) :407-413
[10]   A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877